Clinical Trials
12 trialsNCT00720356 2018-10-26
Bevacizumab and Erlotinib After Radiation Therapy and Temozolomide in Treating Patients With Newly Diagnosed Glioblastoma Multiforme or Gliosarcoma
Northwestern University
Phase 2 Completed
NCT00187486 2017-09-05
Safety and Efficacy Study of Tarceva, Temodar, and Radiation Therapy in Patients With Newly Diagnosed Brain Tumors
University of California, San Francisco
Phase 2 Completed
NCT00086879 2017-07-27
Erlotinib Compared With Temozolomide or Carmustine in Treating Patients With Recurrent Glioblastoma Multiforme
European Organisation for Research and Treatment of Cancer - EORTC
Phase 2 Completed
NCT00445588 2016-04-27
Erlotinib and Sorafenib in Treating Patients With Progressive or Recurrent Glioblastoma Multiforme
National Cancer Institute (NCI)
Phase 2 Completed
NCT00525525 2014-11-14
AVF4120s
University of California, San Francisco
Phase 2 Completed
NCT00337883 2014-03-04
A Study of the Safety and Efficacy of Tarceva in Patients With First Relapse of Grade IV Glioma (Glioblastoma Multiforme)
Genentech, Inc.
Phase 2 Completed
NCT00054496 2014-01-10
Erlotinib in Treating Patients With Recurrent or Progressive Glioblastoma Multiforme
National Cancer Institute (NCI)
Phase 2 Unknown
NCT00672243 2013-08-07
Ph II Erlotinib + Sirolimus for Pts w Recurrent Malignant Glioma Multiforme
Duke University
Phase 2 Completed
NCT00039494 2013-08-02
Erlotinib and Temozolomide With Radiation Therapy in Treating Patients With Glioblastoma Multiforme or Other Brain Tumors
National Cancer Institute (NCI)
Phase 2 Completed
NCT00387894 2013-06-04
Erlotinib in Treating Patients With Recurrent Glioblastoma Multiforme or Gliosarcoma
University of California, San Francisco
Phase 2 Terminated
NCT00671970 2013-05-13
Phase (Ph) II Bevacizumab + Erlotinib for Patients (Pts) With Recurrent Malignant Glioma (MG)
Duke University
Phase 2 Completed
NCT00274833 2012-12-06
Radiation Therapy, Temozolomide, and Erlotinib in Treating Patients With Newly Diagnosed Glioblastoma Multiforme
Case Comprehensive Cancer Center
Phase 2 Completed